Dyspepsia Pipeline 2025: Therapies, MOA Insights, And Key Clinical Trial Updates By Delveinsight Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Xian-Janssen Pharmaceutical Ltd

(MENAFN- GetNews)

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Dyspepsia pipeline constitutes 2+ key companies continuously working towards developing 2+ Dyspepsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Dyspepsia Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyspepsia Market.

The Dyspepsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Dyspepsia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Dyspepsia treatment therapies with a considerable amount of success over the years.

• Dyspepsia companies working in the treatment market are Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Xian-Janssen Pharmaceutical Ltd., Materia Medica Holding, Novartis, Eisai China Inc., Zeria Pharmaceutical, Dexa Medica Group, Eisai Co., Ltd., Korea United Pharm. Inc., Daewoong Pharmaceutical, Johnson & Johnson, and others, are developing therapies for the Dyspepsia treatment

• Emerging Dyspepsia therapies in the different phases of clinical trials are- Itopride Hydrochloride, FDC Bromopride, Motilitone, YM443, Domperidone, Kolofort, Tegaserod, Cinitapride, Z-338, DLBS2411, Rabeprazole, UI05MSP015CT, DWJ1252, Imonogas, and others are expected to have a significant impact on the Dyspepsia market in the coming years.

• In November 2024, The FDA has approved Emrosi (minocycline hydrochloride extended-release capsules) for treating inflammatory lesions (papules and pustules) of rosacea in adults. In the Phase III MVOR-2 trial, 60% of patients on Emrosi achieved IGA success at week 16, compared to 31% in the doxycycline group (treatment difference: 28% [95% CI, 17–39]) and 27% in the placebo group (treatment difference: 34% [95% CI, 21–47]). The mean reduction in inflammatory lesion counts was -18.1 with Emrosi, -14.6 with doxycycline, and -11.2 with placebo. The most commonly reported side effect was dyspepsia.

Dyspepsia Overview

Dyspepsia refers to a group of symptoms that are related to the upper part of the digestive tract, particularly the stomach. Commonly known as indigestion, dyspepsia can manifest as discomfort or pain in the upper abdomen.

Get a Free Sample PDF Report to know more about Dyspepsia Pipeline Therapeutic Assessment-

Emerging Dyspepsia Drugs Under Different Phases of Clinical Development Include:

• YM443: Astellas Pharma Inc

• Itopride Hydrochloride: Forest Laboratories

• FDC Bromopride: EMS

• Motilitone: Dong-A ST Co., Ltd.

• YM443: Astellas Pharma Inc

• Domperidone: Xian-Janssen Pharmaceutical Ltd.

• Kolofort: Materia Medica Holding

• Tegaserod: Novartis

• Cinitapride: Eisai China Inc.

• Z-338: Zeria Pharmaceutical

• DLBS2411: Dexa Medica Group

• Rabeprazole: Eisai Co., Ltd.

• UI05MSP015CT: Korea United Pharm. Inc.

• DWJ1252: Daewoong Pharmaceutical

• Imonogas: Johnson & Johnson

Dyspepsia Route of Administration

Dyspepsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Dyspepsia Molecule Type

Dyspepsia Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Dyspepsia Pipeline Therapeutics Assessment

• Dyspepsia Assessment by Product Type

• Dyspepsia By Stage and Product Type

• Dyspepsia Assessment by Route of Administration

• Dyspepsia By Stage and Route of Administration

• Dyspepsia Assessment by Molecule Type

• Dyspepsia by Stage and Molecule Type

DelveInsight's Dyspepsia Report covers around 2+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Dyspepsia product details are provided in the report. Download the Dyspepsia pipeline report to learn more about the emerging Dyspepsia therapies

Some of the key companies in the Dyspepsia Therapeutics Market include:

Key companies developing therapies for Dyspepsia are - Bayer, Sumitomo, Cadila Pharmaceuticals, Teva, Johnson & Johnson, Pfizer, Sanofi, AstraZeneca, Jiangsu Aosaikang Pharma, Eisai, Kyowa Kirin Pharmaceuticals, Hanmi Pharm, and others.

Dyspepsia Pipeline Analysis:

The Dyspepsia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dyspepsia with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyspepsia Treatment.

• Dyspepsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Dyspepsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyspepsia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Dyspepsia drugs and therapies

Scope of Dyspepsia Pipeline Drug Insight

• Coverage: Global

• Key Dyspepsia Companies: Astellas Pharma Inc, Forest Laboratories, EMS, Dong-A ST Co., Ltd., Astellas Pharma Inc, Xian-Janssen Pharmaceutical Ltd., Materia Medica Holding, Novartis, Eisai China Inc., Zeria Pharmaceutical, Dexa Medica Group, Eisai Co., Ltd., Korea United Pharm. Inc., Daewoong Pharmaceutical, Johnson & Johnson, and others

• Key Dyspepsia Therapies: Itopride Hydrochloride, FDC Bromopride, Motilitone, YM443, Domperidone, Kolofort, Tegaserod, Cinitapride, Z-338, DLBS2411, Rabeprazole, UI05MSP015CT, DWJ1252, Imonogas, and others

• Dyspepsia Therapeutic Assessment: Dyspepsia current marketed and Dyspepsia emerging therapies

• Dyspepsia Market Dynamics: Dyspepsia market drivers and Dyspepsia market barriers

Request for Sample PDF Report for Dyspepsia Pipeline Assessment and clinical trials

Table of Contents

1. Dyspepsia Report Introduction

2. Dyspepsia Executive Summary

3. Dyspepsia Overview

4. Dyspepsia- Analytical Perspective In-depth Commercial Assessment

5. Dyspepsia Pipeline Therapeutics

6. Dyspepsia Late Stage Products (Phase II/III)

7. Dyspepsia Mid Stage Products (Phase II)

8. Dyspepsia Early Stage Products (Phase I)

9. Dyspepsia Preclinical Stage Products

10. Dyspepsia Therapeutics Assessment

11. Dyspepsia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dyspepsia Key Companies

14. Dyspepsia Key Products

15. Dyspepsia Unmet Needs

16 . Dyspepsia Market Drivers and Barriers

17. Dyspepsia Future Perspectives and Conclusion

18. Dyspepsia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

MENAFN08092025003238003268ID1110033216